Healthcare Industry News: TandemHeart
News Release - November 23, 2009
California Pacific Medical Center Adopts TandemHeart(R)-Versatile Circulatory Support Device From CardiacAssistSAN FRANCISCO--(HSMN NewsFeed)--CardiacAssist Inc. announced today that the Heart Failure and Transplant Program of California Pacific Medical Center (CPMC) has adopted the company’s TandemHeart(R) System.
CPMC is in select company: TandemHeart is now being used in nearly 90% of the “Best U.S. Heart & Heart Surgery Hospitals” as ranked by U.S. News & World Report—with nearly 1,800 TandemHeart procedures performed to date at nearly 150 hospitals across the United States.
“We pride ourselves in being a state-of-the-art cardiac care facility,” said Ernest Haeusslein, M.D., Medical Director of CPMC’s Heart Failure and Transplant Program. “Therefore we are very proud to be one of the first cardiac centers in the state of California to be able to add this important new life-saving technology to the list of resources available to care for our critically ill cardiac patients.”
FDA-cleared TandemHeart can be placed rapidly by both interventional cardiologists in a cath lab and by cardiac surgeons in an operating room to provide short-term circulatory support to patients requiring additional cardiac assistance. The device provides effective and reliable temporary circulatory support for critically ill patients. Hemodynamic support includes a high net blood-flow rate of up to five liters per minute in the catheterization lab or up to eight liters per minute in the OR—more than twice the amount of other available technologies—and is fully reimbursed by Medicare under existing DRG codes.
“TandemHeart establishes a whole new paradigm for treating cardiac patients quickly and aggressively,” said Michael Garippa, CEO and President of CardiacAssist. “Many great hospitals such as CPMC are becoming aware of the significant benefits of TandemHeart for their cardiac patients, which is why we believe more passionately than ever that TandemHeart is destined to become standard of care in extracorporeal circulatory support.”
Headquartered in Pittsburgh, privately held CardiacAssist is a growing and profitable medical technology company that develops, manufactures and markets cardiac assist devices. The Company has developed the world’s first and only proprietary platform, FDA-cleared and CE-Marked TandemHeart(R)—which provides a short-term extracorporeal circulatory support system for both cardiologists and cardiac surgeons.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.